Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Promotion vs. R&Deja vu all over again!Posted: January 7, 2008It's deja vu all over again in the ongoing debate of R&D spending vs. promotional spending by the US pharmaceutical industry. Critics are out again to "prove" that the industry spends much more on promotion than it does on R&D. Back in 2004, I reviewed the book "The Truth About the Drug Companies: How They Deceive Us and What to do About It," in which the author Marcia Angell, MD, offered proof that R&D takes a back seat to promotion in the drug industry. Now, there's a "new" study by two Canadian authors entitled "The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States," which was recently published in PLoS Medicine. I have a problem with the methodology employed in this analysis and have come up with my own "new new" estimate of pharma promotional spending. For the details, read today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Physician Education Key Opinion Leaders, Medical Science Liaisons, & CME
It's a new era for pharmaceutical company support of physician education. New guidelines and regulations from various governmental and non-governmental regulatory bodies have come into play during the past few years. The second event defining this new era was the withdrawal of Vioxx from the market in 2004 and the subsequent re-emergence of the importance of physicians as "learned intermediaries."
More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals. This Special Supplement to Pharma Markeing News is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process. Order and pay for this Special Supplement now using your credit card ONLY $29.95
If you wish to pay by check or credit card off-line, please use: |